to deploy Corazyme™
Wastewater is wasted.
Fuel logistics are failing
Defense, aviation, and industrial sectors face foreign supply chains, volatile pricing, and regulatory risk. Most alternatives require heavy infrastructure and years to deploy.
Waste is a liability
Municipalities pay to haul away sludge that carries untapped energy value. Every city generates it continuously — at no additional cost.
There is no bridge
Current alt-fuel solutions demand new construction, combustion-heavy processes, or agricultural inputs — all high cost and slow to scale.
Corazyme™ closes the gap.
A modular enzymatic system that attaches to existing wastewater infrastructure. No new construction. No combustion. No agricultural inputs. Specification-compliant fuel output from day one.
| Company | Modular | No combustion | Non-food feedstock | No new construction | Drop-in compatible | Immediate revenue |
|---|---|---|---|---|---|---|
| Corazyme™ / OREVO | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| LanzaJet | — | — | ✓ | — | ✓ | — |
| Fulcrum Bioenergy | — | — | ✓ | — | ✓ | — |
| Gevo | — | ✓ | — | — | ✓ | — |
| Traditional biofuel | — | — | — | — | ✓ | — |
No new construction.
Wastewater sludge
Municipal and industrial facilities generate sludge continuously. Already collected, already on-site. No feedstock logistics. No procurement costs. The input is the liability cities already pay to remove.
Enzymatic platform
Corazyme™ uses a proprietary enzyme system to convert biogenic carbon at ambient temperature and pressure. No gasification, no combustion. The modular unit retrofits directly to existing infrastructure.
Fossil-identical fuel
Specification-compliant renewable diesel, SAF, and gasoline. Drop-in compatible with existing pipelines, refineries, and engines. No modifications required anywhere downstream.
Scalable fuel revenue.
Bench-scale complete
Platform validated. IP secured. Yield and cost profile confirmed.
CompletePilot in progress
Active conversations in Minneapolis, Vacaville, and Seattle. DOE grants pending.
In progressCommercial prep
First commercial module funded by Series A. Site integration and fuel qualification.
Series AScaled rollout
35 modules across cities and bases within 7 years. $154M revenue. $86M EBITDA.
Year 7into this thesis.
Chevron $3B in renewable fuels · $3.15B acquisition of REG
ExxonMobil $17B committed to low-carbon through 2027
BP $4B into bioenergy · $1.3B acquisition of Archaea
Shell $10B in low-carbon fuels
Majors targeting technologies that solve feedstock, CI, and scalability constraints.
✓ Secure, low-cost, high-volume feedstock
✓ Drop-in molecules for existing infrastructure
✓ Low CI pathways aligned with mandates
✓ Modular, multi-site deployment capability
Corazyme™ aligns directly with acquisition theses of global energy buyers.
✓ Municipal sludge: stable, low-cost feedstock
✓ Modular units replicate nationally and globally
✓ Fossil-identical fuels meet all downstream specs
✓ CI profile meets 45Z threshold
45Z requires <50 kg CO₂e per mmBTU. Corazyme™ meets threshold.
✓ Credit applies to each gallon produced
✓ Drives materially higher per-module EBITDA
✓ Strengthens strategic buyer economics
✓ Increases exit valuation basis
first commercial module.
Series A capital builds the first commercial Corazyme™ module.
Funds site integration, enzyme optimization, and regulatory steps required for full fuel qualification.
2.5 — 3 year runway. Establishes a commercial blueprint replicable across cities and military bases nationwide.
generates material EBITDA and exit potential.
first-of-kind molecular systems.
Unexpected origin.
